Get startedLog in
    Picture of Inmune Bio logo

    INMB — Inmune Bio News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapMomentum Trap
    All News

    INmune Bio Inc expected to post a loss of 47 cents a share - Earnings Preview

    Picture of Inmune Bio logoInmune Bio
    05/05/2025 12:18
    INmune Bio Inc INMB.OQ INMB.O is expected to show a fall in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for INmune Bio Inc is for a loss of 47 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 3.6% in the last three months. ​

Wall Street's median 12-month price target for INmune Bio Inc is $23.00​, above​ its last closing price of $7.76. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​


    QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATEACTUALBEAT, MET, MISSEDSURPRISE %
    Dec. 31 2024-0.54-0.40Beat25.9
    Sep. 30 2024-0.48-0.50-0.60Missed-20.8
    Jun. 30 2024-0.63-0.63-0.50Beat20.6​
    Mar. 31 2024-0.53-0.53-0.61Missed-14
    ​​Dec. 31 2023-0.44-0.47Missed-6.8
    Sep. 30 2023-0.39-0.39-0.48Missed-21.5​
    Jun. 30 2023-0.39-0.40-0.36Beat9.2
    Mar. 31 2023-0.02-0.02-0.36Missed-1,700
    

This summary was machine generated May 5 at 11:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

    Recent news on Inmune Bio

    See all news